RT Journal Article
SR Electronic
T1 Development of a quantitative antigen assay to detect coccidioidal chitinase-1 (CTS1) in human serum
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.14.21257226
DO 10.1101/2021.05.14.21257226
A1 Grill, Francisca J.
A1 Grys, Thomas E.
A1 Grill, Marie F.
A1 Roeder, Alexa
A1 Blair, Janis E.
A1 Lake, Douglas F.
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.14.21257226.abstract
AB Background Coccidioidomycosis is often diagnosed with a collection of tests that rely on the patient’s ability to mount an immune response to the fungus (antibody-based diagnostics), making diagnosis of this infection challenging. Here we present an antigen-based assay that detects and quantifies coccidioidal chitinase-1 (CTS1) in human serum.Methods An inhibition-based enzyme-linked immunoassay (ELISA) was developed that utilizes a monoclonal antibody specific for coccidioidal CTS1. CTS1 was quantified in commercial antigen preparations using recombinant CTS1 as a standard. Sera from 192 individuals from an endemic area were tested which included 78 patients (40.6%) with proven or probable coccidioidomycosis.Results The quantity of CTS1 in diagnostic commercial antigen preparations from different suppliers varied. CTS1 antigenemia was detected in 87.2% of patients with proven or probable coccidioidomycosis. Specificity was determined to be 96.94% using serum from individuals who reside in the Phoenix, Arizona area who did not have coccidioidomycosis. Levels of CTS1 correlated with low- and high-titer serology from patients with a coccidioidomycosis diagnosis.Conclusions Since the CTS1 inhibition ELISA described in this report does not depend on the host immune response, it is a promising diagnostic tool to aid in diagnosis and disease monitoring of coccidioidomycosis.Summary Diagnosis of coccidioidomycosis often relies on the host’s ability to mount an immune response. Here we present an antigen-based assay that detects and quantifies coccidioidal chitinase-1 in human serum to diagnose coccidioidomycosis independent of host immune status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Arizona Biomedical Research Commission [ADHS16-162513] and the Mayo Clinic Center for Individualized Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ASU IRB 0601000548 and Mayo Clinic IRB 12-000965All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is provided in manuscript (no external links).